Selonsertib

Drug Profile

Selonsertib

Alternative Names: ASK1 inhibitor - Gilead Sciences; GS-4977; GS-4997

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Benzamides; Cardiovascular therapies; Imidazoles; Pyridines; Triazoles
  • Mechanism of Action MAP kinase kinase kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II Alcoholic hepatitis; Diabetic nephropathies; Non-alcoholic fatty liver disease; Pulmonary arterial hypertension

Most Recent Events

  • 19 Apr 2017 Phase-I clinical trials in Non-alcoholic steatohepatitis (Combination therapy, In volunteers) in USA (PO) before April 2017
  • 19 Apr 2017 Pharmacokinetics and adverse events data from a phase I trial in Non-alcoholic steatohepatitis presented at The International Liver Congress 2017 (ILC-2017)
  • 19 Apr 2017 Gilead sciences completes enrolment in a phase I trial for Non-alcoholic steatohepatitis (In volunteers, Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top